Jeffrey Hubauer

The tool offers governments and humanitarian organizations critical lead time to deliver life-saving food, health care, and supplies to at-risk areas. It achieves 89% accuracy when forecasting one month out and maintains 86% accuracy over six months — a significant improvement over simpler baseline models that rely only on recent historical child malnutrition prevalence trends. https://lnkd.in/e6x5_Pt4 #AI #childmalnutrition #malnutrition #health #healthcare

1

PTM / MD Plastics Joins International Healthcare Tech Delegation, Announces Expansion in Tucson Tucson, AZ – [5/12/25] – PTM / MD Plastics recently participated in the International Healthcare Tech Delegation at the University of Arizona, where company representatives had the opportunity to connect with leaders in the life sciences industry and the broader healthcare community. Among those present was Tucson Mayor Regina Romero, highlighting the event’s importance in fostering innovation and collaboration within the sector. During the event, Francisco Navarro, CEO of MD Plastics, shared exciting news about the company's expansion into Tucson under its newly established Medical Device Plastics division. The expansion is aimed at supporting medical manufacturing companies in the region, reinforcing MD Plastics' commitment to high-quality production and cutting-edge technology in healthcare solutions. Francisco Xavier Navarro Jr., Design Engineer, expressed enthusiasm for the new phase of development, emphasizing that the Medical Device Plastics facility will specialize in thermoplastic and silicone manufacturing within a clean-room environment, ensuring stringent quality standards for medical applications. The Tucson facility is scheduled to begin operations in late Q4 of 2025, positioning MD Plastics as a strategic partner for medical manufacturers seeking reliable, cost-effective, and innovative production solutions.

66

14 Comments

Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period. Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period. Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. “We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter,” said Brian Webster, President and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial organization, enhancing our revenue cycle management capabilities, and expanding gross margin. As we progress on our journey to category leadership, we remain focused on both market share capture and growing the wearable defibrillator market, while executing on our commitments to patients and their prescribers.” First Quarter Fiscal 2026 Financial Results Total revenue was $19.4 million, an increase of 52% compared to the prior year period. 4,205 prescriptions were written for the ASSURE® system, an increase of 51% compared to the prior year period. Revenue growth was driven by higher market share with existing customers and activation of new accounts. Revenue also benefited from a higher mix of in-network patients and improvements in revenue cycle management capabilities. Gross profit was $8.9 million compared to $4.2 million in the prior year period. Gross margin expanded to 45.7% compared to 32.9% in the prior year period, driven by volume leverage and a higher mix of in-network patients. GAAP operating expenses were $37.7 million and included $2.9 million of non-recurring new public company costs. GAAP operating expenses were $22.6 million in the prior year period. Excluding non-recurring new public company costs and share-based compensation expense, operating expenses were $30.3 million in Q1 FY26. The increase was attributable to growth in expenses related to commercial and revenue cycle resources. GAAP net loss and comprehensive loss was $25.8 million compared to GAAP net loss and comprehensive loss of $20.3 million in the prior year period. Adjusted EBITDA* loss was $19.4 million compared to an adjusted EBITDA loss of $15.7 million in the prior year period. Cash and cash equivalents totaled $201.2 million as of July 31, 2025. Fiscal Year 2026 Revenue Guidance Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. This compares to prior FY26 revenue guidance of $85 million.

121

6 Comments

I had the opportunity this weekend to present SJC Bio at the SoCal Dental Innovators Networking Day. The discussion centered around a simple question: What if stability came first in bone regeneration instead of last? For decades, dental grafting has followed a biology-first model where clinicians wait months for healing before mechanical stability emerges. At SJC Bio we are exploring the reverse approach — stability first, bone regeneration follows. Great conversations with clinicians, investors, and innovators across the dental community.

16

7 Comments

Had the pleasure of sitting down with Dave Coffaro from the Greater Irvine Chamber to talk about medtech innovation globally and in Orange County —specifically, the potential of therapeutic ultrasound to transform care. We discussed how non-invasive technologies like ours can help patients avoid surgery, reduce risk, and improve outcomes—while also strengthening Orange County’s role as a hub for health innovation. I’m especially glad to see that the Greater Irvine Chamber has identified MedTech as a top industry focus in its strategic plan for regional growth. MedTech doesn’t just save and improve lives—it drives innovation, fuels economic development, and creates high-paying jobs. Grateful for the Chamber’s leadership in supporting our growing medtech ecosystem. The future of healthcare is being built right here. Listen now on the app, website, or your favorite podcast platform: https://lnkd.in/gCevh4Ag #MedTech #Innovation #TherapeuticUltrasound #NonInvasiveCare #OrangeCounty #HealthcareLeadership #EconomicGrowth

60

3 Comments

This week’s exhibition in Anaheim was a great chance to reconnect with colleagues and industry partners. One clear theme emerged: subcontractors and raw material suppliers are balancing focus on their core expertise with the need to deliver greater value to customers. Today, vertical integration is becoming the leading strategy—reducing supply‑chain friction while creating meaningful customer value. At Medibrane Ltd, we’ve always invested in strengthening our internal technologies to create clinical value and competitive advantage for our OEM's . Still, we know that customers ultimately define what true value is. So we’d love to hear from you: What are the main risks or development constraints you face when designing new medical devices? • Hemodynamics, Thrombosis & Biological Response • Delivery Dynamics & Mechanical Deployment • Implant Mechanical Failure • Implant–Tissue Interface •Getting truly consistent output from subcontractors and material suppliers Feel free to share your thoughts!

14

2 Comments

Keck School of Medicine of the University of Southern California’s 10th Annual Advanced Endoscopic & Endoluminal Surgery Course brought together colorectal surgery fellows and faculty for an immersive, hands-on program focused on refining advanced techniques and exploring evolving approaches in minimally invasive care. A key highlight of this year’s course was the 3D TAMIS training station, featuring depth-enhanced visualization using AED EndoPro 3D. In collaboration with FUJIFILM Healthcare Americas Corporation and Applied Medical, participants gained an immersive perspective on transanal surgery. Other stations highlighted advanced procedures with Erbe USA Incorporated, Boston Scientific, Olympus Corporation, and Stryker. Dr. Sang Lee, Chief of Colorectal Surgery at USC, emphasizes that advancing colorectal surgery depends on bringing surgeons together to learn, refine techniques, and continuously elevate patient care.

8

1 Comment

Proud to be featured by MedTech Strategist as a presenter at its Innovation Summit this November. For U.S. investors who have not yet met us: ViCentra is redefining insulin pump care with Kaleido, the smallest, lightest, and most precise insulin patch pump in its class. We’ve recently raised $85M in the first close of our series D and are using those funds to scale manufacturing, expand across Europe and prepare for US market entry. We’re now raising the final leg of our Series D in a second close. If you’d like to connect in person or virtually, please reach out. I’d welcome the chance to share our vision, traction, and how Kaleido fits into the U.S. diabetes landscape. #MedTech #Diabetes #InsulinPump #SeriesD #Vicentra #Kaleido

68

2 Comments